When and which patients should receive remdesivir?
- 2 May 2022
- journal article
- editorial
- Published by Elsevier BV in The Lancet
- Vol. 399 (10339), 1918-1920
- https://doi.org/10.1016/s0140-6736(22)00789-9
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analysesThe Lancet, 2022
- SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivoNature, 2022
- Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsThe New England Journal of Medicine, 2021
- Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance — COVID-NET, 14 States, January–August 2021Morbidity and Mortality Weekly Report (MMWR), 2021
- High-value laboratory testing for hospitalized COVID-19 patients: a reviewFuture Virology, 2021
- SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasionNature, 2021
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial ResultsThe New England Journal of Medicine, 2021
- Remdesivir for the Treatment of Covid-19 — Final ReportThe New England Journal of Medicine, 2020
- Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019Clinical Infectious Diseases, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020